SCHOLAR ROCK HOLDING CORPORATION Research and Development Expense
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Research and Development Expense of $58.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- SCHOLAR ROCK HOLDING CORPORATION research and development expense for the quarter ending 2026-06-30 was $58.23M, a 6.68% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION research and development expense for the quarter ending 2026-03-31 was $51.81M, a 6.44% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION research and development expense for the quarter ending 2025-12-31 was $46.88M, a 6.93% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION research and development expense for the quarter ending 2025-09-30 was $50.49M, a 3.63% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION research and development expense for fiscal 2025 was $208.44M, a 12.95% increase from fiscal 2024.
- SCHOLAR ROCK HOLDING CORPORATION research and development expense for fiscal 2024 was $184.55M, a 51.39% increase from fiscal 2023.
- SCHOLAR ROCK HOLDING CORPORATION research and development expense for fiscal 2023 was $121.90M, a 2.04% decline from fiscal 2022.
- SCHOLAR ROCK HOLDING CORPORATION research and development expense for fiscal 2022 was $124.44M, a 14.73% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $58.23M 10-Q · filed 2026-08-06 | $110.05M 10-Q · filed 2026-08-06 | $156.92M derived: sum of 3 quarters · filed 2026-08-06 | $207.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $51.81M 10-Q · filed 2026-05-07 | $98.69M derived: sum of 2 quarters · filed 2026-05-07 | $149.18M derived: sum of 3 quarters · filed 2026-05-07 | $211.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $46.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $97.36M derived: sum of 2 quarters · filed 2026-03-03 | $159.76M derived: sum of 3 quarters · filed 2026-08-06 | $208.44M 10-K · filed 2026-03-03 |
| 2025-09-30 | $50.49M 10-Q · filed 2025-11-14 | $112.89M derived: sum of 2 quarters · filed 2026-08-06 | $161.56M 10-Q · filed 2025-11-14 | $211.93M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $62.40M 10-Q · filed 2026-08-06 | $111.08M 10-Q · filed 2026-08-06 | $161.44M derived: sum of 3 quarters · filed 2026-08-06 | $210.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $48.68M 10-Q · filed 2026-05-07 | $99.04M derived: sum of 2 quarters · filed 2026-05-07 | $147.76M derived: sum of 3 quarters · filed 2026-05-07 | $190.13M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $50.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $99.08M derived: sum of 2 quarters · filed 2026-03-03 | $141.46M derived: sum of 3 quarters · filed 2026-03-03 | $184.55M 10-K · filed 2026-03-03 |
| 2024-09-30 | $48.72M 10-Q · filed 2025-11-14 | $91.09M derived: sum of 2 quarters · filed 2025-11-14 | $134.19M 10-Q · filed 2025-11-14 | $169.15M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $42.37M 10-Q · filed 2025-08-06 | $85.47M 10-Q · filed 2025-08-06 | $120.43M derived: sum of 3 quarters · filed 2025-08-06 | $150.76M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $43.09M 10-Q · filed 2025-05-14 | $78.06M derived: sum of 2 quarters · filed 2025-05-14 | $108.39M derived: sum of 3 quarters · filed 2025-05-14 | $135.26M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $34.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $65.30M derived: sum of 2 quarters · filed 2025-02-27 | $92.17M derived: sum of 3 quarters · filed 2025-02-27 | $121.90M 10-K · filed 2025-02-27 |
| 2023-09-30 | $30.34M 10-Q · filed 2024-11-12 | $57.20M derived: sum of 2 quarters · filed 2024-11-12 | $86.94M 10-Q · filed 2024-11-12 | $116.55M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $26.87M 10-Q · filed 2024-08-08 | $56.60M 10-Q · filed 2024-08-08 | $86.22M derived: sum of 3 quarters · filed 2024-08-08 | $119.61M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $29.73M 10-Q · filed 2024-05-07 | $59.35M derived: sum of 2 quarters · filed 2024-05-07 | $92.74M derived: sum of 3 quarters · filed 2024-05-07 | $124.81M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $29.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $63.01M derived: sum of 2 quarters · filed 2024-03-19 | $95.08M derived: sum of 3 quarters · filed 2024-03-19 | $124.44M 10-K · filed 2024-03-19 |
| 2022-09-30 | $33.39M 10-Q · filed 2023-11-07 | $65.47M derived: sum of 2 quarters · filed 2023-11-07 | $94.83M 10-Q · filed 2023-11-07 | $123.88M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $32.07M 10-Q · filed 2023-08-09 | $61.44M 10-Q · filed 2023-08-09 | $90.49M derived: sum of 3 quarters · filed 2023-08-09 | $121.75M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $29.37M 10-Q · filed 2023-05-09 | $58.42M derived: sum of 2 quarters · filed 2023-05-09 | $89.68M derived: sum of 3 quarters · filed 2023-05-09 | $115.28M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $29.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $60.32M derived: sum of 2 quarters · filed 2023-03-07 | $85.92M derived: sum of 3 quarters · filed 2023-03-07 | $108.47M 10-K · filed 2023-03-07 |
| 2021-09-30 | $31.27M 10-Q · filed 2022-11-14 | $56.87M derived: sum of 2 quarters · filed 2022-11-14 | $79.42M 10-Q · filed 2022-11-14 | $101.20M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $25.60M 10-Q · filed 2022-08-08 | $48.15M 10-Q · filed 2022-08-08 | $69.93M derived: sum of 3 quarters · filed 2022-08-08 | $88.31M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $22.55M 10-Q · filed 2022-05-16 | $44.33M derived: sum of 2 quarters · filed 2022-05-16 | $62.71M derived: sum of 3 quarters · filed 2022-05-16 | $79.71M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $21.78M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $40.16M derived: sum of 2 quarters · filed 2022-03-07 | $57.16M derived: sum of 3 quarters · filed 2022-03-07 | $74.06M 10-K · filed 2022-03-07 |
| 2020-09-30 | $18.38M 10-Q · filed 2021-11-09 | $35.38M derived: sum of 2 quarters · filed 2021-11-09 | $52.28M 10-Q · filed 2021-11-09 | $66.35M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $17.00M 10-Q · filed 2021-08-10 | $33.90M 10-Q · filed 2021-08-10 | $47.96M derived: sum of 3 quarters · filed 2021-08-10 | $63.66M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $16.90M 10-Q · filed 2021-05-13 | $30.97M derived: sum of 2 quarters · filed 2021-05-13 | $46.66M derived: sum of 3 quarters · filed 2021-05-13 | $60.38M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $14.06M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $29.76M derived: sum of 2 quarters · filed 2021-03-09 | $43.48M derived: sum of 3 quarters · filed 2021-03-09 | $54.22M 10-K · filed 2021-03-09 |
| 2019-09-30 | $15.70M 10-Q · filed 2020-11-09 | $29.41M derived: sum of 2 quarters · filed 2020-11-09 | $40.15M 10-Q · filed 2020-11-09 | $50.28M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $13.71M 10-Q · filed 2020-08-07 | $24.45M 10-Q · filed 2020-08-07 | $34.58M derived: sum of 3 quarters · filed 2020-08-07 | $42.64M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | $10.74M 10-Q · filed 2020-05-07 | $20.86M derived: sum of 2 quarters · filed 2020-05-07 | $28.93M derived: sum of 3 quarters · filed 2020-05-07 | $40.35M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $10.13M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $18.19M derived: sum of 2 quarters · filed 2020-03-12 | $29.61M derived: sum of 3 quarters · filed 2020-03-12 | $36.31M 10-K · filed 2020-03-12 |
| 2018-09-30 | $8.06M 10-Q · filed 2019-11-12 | $19.48M derived: sum of 2 quarters · filed 2019-11-12 | $26.18M 10-Q · filed 2019-11-12 | $33.07M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $11.42M 10-Q · filed 2019-08-14 | $18.13M 10-Q · filed 2019-08-14 | $25.01M derived: sum of 3 quarters · filed 2019-08-14 | $29.79M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $6.70M 10-Q · filed 2019-05-15 | $13.59M derived: sum of 2 quarters · filed 2019-05-15 | $18.37M derived: sum of 3 quarters · filed 2019-05-15 | $23.08M derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | $6.89M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-19 | $11.66M derived: sum of 2 quarters · filed 2019-03-19 | $16.38M derived: sum of 3 quarters · filed 2019-03-19 | $19.94M 10-K · filed 2019-03-19 |
| 2017-09-30 | $4.78M 10-Q · filed 2018-11-08 | $9.49M derived: sum of 2 quarters · filed 2018-11-08 | $13.06M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $4.71M 10-Q · filed 2018-08-08 | $8.28M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |